FINTEPLA (Fenfluramine) approved by EU Commission for use in Dravet Syndrome
The European Commission has approved the use of a new drug as an add-on therapy for the treatment of Dravet Syndrome in patients 2 years and older.
The Commission’s approval of FINTEPLA (Fenfluramine) will mean that the drug’s manufacturers can now apply to European member states regulatory authorities to make the drug available and/or reimbursed in that country.

We are delighted to have been listed as a local patient partner in the development of a National Public & Patient Involvement (PPI) Network.
Further to our